Interview with Mal Eutick, CEO, Phebra Australia
Can you start by giving our readers a brief overview of the company’s history here and your most notable…
Phebra Australia
Last updated: 13.02.2014
Address: 332 Burns Bay Road, Lane Cove, NSW 2066, Australia
Tel: +61 (0) 2 9420 9199
Web: http://www.phebra.com.au/
Company description
Phebra specialises in the development, manufacture, marketing and distribution of highly specialised and innovative medicines for the hospital market.
At Phebra, our inspiration and commitment comes from providing medicines for serious and life-threatening conditions. We pride ourselves in developing and providing high quality pharmaceuticals to meet the requirements of the hospital specialty pharmaceutical market.
Phebra markets a range of pharmaceuticals in important disease areas such as anti-infectives, antidotes, diagnostic dyes and agents, oncology, pain and other specialty pharmaceuticals.
Our products are distributed in Australia, New Zealand, Asia, Canada and Europe.
Products and services
At Phebra, our inspiration and commitment comes from providing medicines for serious and life-threatening conditions. We pride ourselves in developing and providing high quality pharmaceuticals to meet the requirements of the hospital specialty pharmaceutical market.
Phebra markets a range of products in the following therapeutic areas:
anti-infectives
antidotes
cardiovascular and respiratory disease
central nervous system
diagnostic dyes and agents
infusion solutions, intravenous additives and electrolyte replacement solutions
oncology and pain
vitamins
specialty pharmaceuticals
Interviews
Related
Australia / Opportunities for the Life Science Industry post-COVID
Regular PharmaBoardroom contributor Brendan Shaw outlines how his home country of Australia has so far successfully…
Australia / Growing Clinical Trials Even in Pandemic’s Wake
In an exclusive new podcast, DIA Global Forum Australia/New Zealand Regional Editor Richard Day (University of…
Opinion / The Powerful Impact of Taking a Patient-Centric Approach in an Evolving Health Landscape
Janssen Australia & New Zealand’s Bruce Goodwin argues that greater adoption of patient-centric practices…
Interview with Mal Eutick, CEO, Phebra Australia
Can you start by giving our readers a brief overview of the company’s history here and your most notable…
Interview with Marisa Petersen, Managing Director, George Clinical, Australia
Would you begin by outlining the role & importance of George Clinical within the George Institute, highlighting…
Interview with Vlado Perkovich, Executive Director, The George Institute,…
Would you begin by giving an introduction to our international readers of the institute, highlighting recent…
Interview with John Chalmers, Senior Director, The George Institute
For those that are not familiar with your name, would you start by introducing yourself? After obtaining my PhD in…
Interview with Megan Fookes, Director, Rare Voices
Rare Voices Australia is a new organisation that has been established after the national rare diseases symposium in…
Australia: Where Value Beats Cost
In some ways the Australian medicines industry is going through the same restructuring and challenges as the…
Interview with Craig Moore, Director, Hahn Healthcare
Can you outline the significance of the current PBS to the industry and in particular the impact it has on service…
Interview with Radek Sali, CEO, SWISSE
Speaking to the Australian environment, how would you rate the market in terms of companies like Swisse? After…
Interview with Albert Spanos, General Manager, Celgene Australia
In our interviews we have been hearing two opinions on the success of PBS reforms: that it works as it should in…
